VAPOTHERM INC
VAPOHealthcare · Surgical & Medical Instruments & Apparatus · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $68.7M | $66.8M | $113.3M | $125.7M | $48.1M | $42.4M |
| Operating income | −$39.1M | −$100.4M | −$57.2M | −$43.0M | −$48.2M | −$8.4M |
| Net income | −$58.2M | −$113.3M | −$59.8M | −$51.5M | −$51.1M | −$8.9M |
| Total assets | $77.6M | $96.2M | $160.1M | $215.7M | $111.9M | $97.2M |
| Total liabilities | $133.0M | $124.4M | $93.4M | $101.8M | $58.2M | $45.7M |
| Equity | −$55.3M | −$28.2M | $66.7M | $113.9M | $53.7M | $51.6M |
| EPS (diluted) | $-9.64 | $-33.89 | $-2.31 | — | — | — |
| Shares out. | 46.2M | 26.2M | 25.8M | 20.9M | 20.9M | 16.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −56.9%
- Net margin
- −84.7%
- Return on equity
- 105.2%
- Return on assets
- −75.0%
- Return on capital (ROCE)
- −66.8%
- Liabilities / assets
- 171.3%
- Debt / equity
- —
- Book value / share
- $-1.20
- Revenue growth (YoY)
- 2.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -24.54distress
- Accruals / assets
- −43.7%clean
- Beneish M-Score
- -4.64normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Arnerich Anthony L.Director | Sep 20, 2024 | D | 9,179 | — |
| Army JosephOfficer — President and CEO | Sep 20, 2024 | D | 392,094 | — |
| Landry JohnOfficer — SVP & Chief Financial Officer | Sep 20, 2024 | D | 45,511 | — |
| Lawrence BrianOfficer — SVP & Chief Technology Officer | Sep 20, 2024 | D | 22,869 | — |
| Mckay DorotaOfficer — VP, Controller and CAO | Sep 20, 2024 | D | 4,625 | — |
| Liken James WDirector | Jan 22, 2024 | Sell | 17,500 | $0.91 |
| Weatherman Elizabeth HDirector | Sep 20, 2024 | D | 14,555 | $2.18 |
| Knowles Lori LynnDirector | Sep 20, 2024 | D | 7,862 | $2.18 |
| Moynihan Mary BethDirector | Sep 20, 2024 | D | 8,352 | $2.18 |
| Berry Lance ADirector | Sep 20, 2024 | D | 22,485 | $2.18 |
| Spence Donald JDirector | Sep 20, 2024 | D | 9,696 | $2.18 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventSep 20, 2024
- Shareholder voteSep 19, 2024
- Results of operationsAug 12, 2024
- Entered a material agreement · New financial obligation · Director / officer changeJun 20, 2024
- Results of operationsMay 9, 2024
- Entered a material agreement · New financial obligation · Regulation FD disclosureApr 1, 2024
- Director / officer changeFeb 27, 2024
- Results of operationsFeb 22, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ANov 14, 2024
- SCHEDULE 13GNov 14, 2024
- SCHEDULE 13G/ANov 14, 2024
- SC 13G/ANov 13, 2024
- SC 13G/ANov 13, 2024
- SC 13G/ANov 12, 2024
- 15-12GFORM 15-12GSep 25, 2024
- EFFECTSep 24, 2024
- EFFECTSep 24, 2024
- EFFECTSep 24, 2024
- SC 13D/ASep 24, 2024
- 4PRIMARY DOCUMENTSep 24, 2024
- 4PRIMARY DOCUMENTSep 24, 2024
- 4PRIMARY DOCUMENTSep 24, 2024
- 4PRIMARY DOCUMENTSep 24, 2024